Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-27
DOI
10.1038/s41598-019-48826-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
- (2019) Shulun Chen et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Fragment-based screening of programmed death ligand 1 (PD-L1)
- (2019) Evan Perry et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function
- (2018) Peter T. Sage et al. JOURNAL OF IMMUNOLOGY
- Structure-function analysis of immune checkpoint receptors to guide emerging anticancer immunotherapy
- (2018) Rita Acúrcio et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
- (2018) Franz L. Ricklefs et al. Science Advances
- Revealing the atomistic details behind the binding of B7–1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study
- (2018) Aravindhan Ganesan et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
- (2018) Pottayil G. Sasikumar et al. BIODRUGS
- A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)
- (2018) Shabnam Shaabani et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
- (2018) Jeffrey Yang et al. MEDICINAL RESEARCH REVIEWS
- The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
- (2018) William G. Kerr et al. JOURNAL OF IMMUNOLOGY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
- (2017) William K. Decker et al. Frontiers in Immunology
- Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
- (2017) Isobel S. Okoye et al. Frontiers in Immunology
- PD-L1 inhibitors in the pipeline: Promise and progress
- (2017) Vito Vanella et al. OncoImmunology
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
- (2016) Mei-Miao Zhan et al. DRUG DISCOVERY TODAY
- Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
- (2016) Tryfon Zarganes-Tzitzikas et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
- (2015) James A. Maier et al. Journal of Chemical Theory and Computation
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein–Protein Interactions
- (2014) Elisa Barile et al. CHEMICAL REVIEWS
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Improved Generalized Born Solvent Model Parameters for Protein Simulations
- (2013) Hai Nguyen et al. Journal of Chemical Theory and Computation
- Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation
- (2012) Dawei Cai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibitory Receptors on Lymphocytes: Insights from Infections
- (2012) P. M. Odorizzi et al. JOURNAL OF IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cell Signaling Targets for Enhancing Regulatory or Effector Function
- (2012) F. Pan et al. Science Signaling
- The role of the PD-1 pathway in autoimmunity and peripheral tolerance
- (2011) Brian T. Fife et al. Annals of the New York Academy of Sciences
- Molecular Interaction Studies Using Microscale Thermophoresis
- (2011) Moran Jerabek-Willemsen et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Qualitative and quantitative studies on human B7.1-Fc fusion protein and the application in pharmacokinetic study in rhesus monkeys
- (2010) Zhihang Chen et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started